Recently, the FDA has approved two new immunotherapy-chemotherapy options for patients with primary advanced or recurrent endometrial cancer. One of these options is the PD-1-directed immune checkpoint inhibitor pembrolizumab, also known as Keytruda. This drug has been approved in combination with carboplatin and paclitaxel for patients with either mismatch repair (MMR)-deficient or MMR-proficient disease. The
The pharmaceutical giant, Eli Lilly, has seen a surge in demand for its weight loss and diabetes treatments over the past year, propelling the company to new heights. The success of their diabetes injection, Mounjaro, and the recently launched obesity drug, Zepbound, has been a significant contributing factor to this upward trajectory. Anat Ashkenazi, the